The effect of silymarin (milk thistle) on cirrhosis: A systematic review and meta-analysis of clinical trials
Hepatology Forum · 2026 · 7 (4) · 374-392
DOI: 10.14744/hf.2025.81811 ↗Abstract
Background and Aim: Cirrhosis is a fatal liver disease. Silymarin, by improving inflam-mation, oxidative stress, and the regeneration of liver cells, can improve cirrhosis. There-fore, this study aimed to conduct a systematic review and meta-analysis of silymarin in cirrhosis. Materials and Methods: PubMed, Scopus, and Web of Science were systematically searched up to 16 May 2025 to find clinical trials that investigated the effect of silymarin on cirrhosis. No time or language limitations were considered. Results: Eight clinical trials with nine intervention arms were included. The results of this study showed that silymarin significantly reduced aspartate aminotransferase (AST) (weighted mean difference [WMD]: −5.41 IU/L, 95% confidence interval [CI]: −8.92, −1.91; I²=89.4%, P for heterogeneity
EUVIMED